Articles tagged with Drug Development
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
Researchers at the University of Virginia Health System are developing computer models to better understand the cellular processes and gene activity of multi-drug resistant bacteria Staphylococcus aureus and Pseudomonas aeruginosa. The goal is to identify vulnerabilities in these bacteria and advance the development of new treatments.
A University at Buffalo-led research team has developed molecules that can transport chloride ions across cell membranes, increasing airway surface liquid and restoring normal mucus clearance in cystic fibrosis cells. The synthetic anion binders offer a new potential treatment for the chronic disease.
The University of Oklahoma is part of a $104 million federal initiative to study antibiotic resistance, led by Harvard Medical School professor Johan Paulsson. The project aims to understand how antibiotic resistance arises and characterize rare cells that survive during antibiotic treatments.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.
Researchers at UVA Health System have developed a powerful new tool to understand how medications affect men and women differently. The model has provided unprecedented insights into biological processes in the liver, helping ensure that new medications will not cause harmful side effects.
USC is partnering with seven leading regenerative medicine institutes to form the Los Angeles and surrounding area regenerative medicine consortium. The partnership aims to advance regenerative medicine using stem cells and gene therapies for treating unmet medical needs.
A University of Virginia team has developed a new analytical tool using hydrogels to cultivate vascular sprouting from mouse lung tissue, providing new insight into idiopathic pulmonary fibrosis. The research aims to understand the biomechanical and biochemical cues to blood vessels in the lungs during disease progression.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
A recent study published in the Journal of Chemical Information and Modeling presents a significant breakthrough in accelerating giga-scale virtual screens using machine learning. The researchers successfully reduced processing time by 10-fold for 1.56 billion drug-like molecules, identifying top-scoring compounds in under ten days.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
Researchers used AI to predict 3D shapes of over 215 million proteins, providing insights into their functions and evolution. The Protein Universe Atlas offers a valuable resource for scientists to explore protein diversity.
Researchers at University of Chicago identified a new pain relief pathway in the brain that produces powerful analgesic effects without tolerance or addictive risks. Targeting acetylcholine receptors, particularly alpha-7, offers a promising path to developing non-opioid painkillers.
Researchers developed a reliable and reproducible real-time live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to predict patients' clinical response to chemotherapy. The study showed improved disease-free survival and reduced recurrence rates in patients who received RT-LTSA sensitive adjuvant regimens.
Researchers at Moffitt will develop novel targeted alpha-particle therapies for uveal melanoma and other rare melanomas. The grant will fund projects aimed at advancing the therapy's efficacy and personalizing its treatment.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
A study by researchers at the University of Tokyo found that the presynaptic Ube3a E3 ligase molecule plays a key role in eliminating neural synapses. This discovery offers insights into developmental disorders such as Angelman syndrome and autism spectrum disorders.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
Researchers at University of California - Riverside uncover COVID's Achilles heel - its dependence on key human proteins. By understanding how the virus interacts with human cells, a new class of antiviral medication may be developed to block replication and treatment.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
A new computational approach removes movement in heart cell and tissue images, allowing direct monitoring of electro-mechanical coupling. The algorithm mimics a drug's action, giving insight into heart diseases.
Researchers are developing a new treatment for ischemic stroke by targeting the prostaglandin receptor EP2, which could have a wider therapeutic window and improve behavioral outcomes. The potential new treatment has the potential to reduce inflammation and provide protection for neurons after an ischemic stroke.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers at Weill Cornell Medicine have discovered a unique site on BK channels that allows small molecules to selectively access the channel, potentially leading to the development of targeted drugs. This finding could help treat a range of diseases, including epilepsy and hypertension.
Researchers have identified a cluster of neurons in the hypothalamus called GABRA5 that regulates energy expenditure. Astrocytes control this cluster, producing tonic GABA that inhibits it, leading to weight gain.
A ferrocene-based capsule with unusual charge-transfer interactions has been synthesized, allowing for reversible encapsulation and release of guest molecules. The capsule can bind to a variety of organic and inorganic dyes and electron-accepting molecules, demonstrating its potential applications in medicine, biotechnology, and chemic...
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A recent study found that the FDA approved 65% of novel drugs in 2022 based on a single clinical trial, while only half of the available studies were classified as randomized clinical trials. This lack of transparency raises concerns about the completeness of the approval process and patient access to accurate information.
Imperial researchers have imaged Piezo1 channels in human cells and organs, revealing their role in regulating blood pressure, respiration, bladder control, and the immune system. This breakthrough could lead to a better understanding of their role in fundamental physiological processes and potentially new drug targets for diseases.
Researchers at Lund University have successfully developed temporary, organic electrodes that can be seamlessly integrated into biological systems. This breakthrough enables the possibility of bioelectronics being implanted in and removed from the body without surgery.
SARS-CoV-2's nucleocapsid protein (N) uses human body temperature to replicate, binding to RNA motifs at specific spatial folds. The study reveals new functions and potential targets for antiviral drugs.
Researchers from the University of Kansas have created a powerful dataset to facilitate drug development against gram-negative bacteria. The dataset reveals over 270,000 previously unidentified outer-membrane proteins with potential as vaccine targets.
Public health experts recommend continuing routine mask-wearing in healthcare settings to protect vulnerable patients and staff from COVID-19. The authors argue that while severe cases have decreased, asymptomatic spread remains a threat, particularly among high-risk patients and healthcare workers who may not be aware they are infected.
A genetic study of 44,396 British people of Bangladeshi and Pakistani ancestry found that 57% have a genetic variant that renders clopidogrel ineffective in preventing recurrent heart attacks. People with two loss of function variants were more than three times more likely to experience recurrent heart attacks due to treatment failure.
A new study by the PhyloBone project at the University of Turku has identified 255 proteins in 30 species of vertebrates that may play a key role in regulating bone formation and regeneration. The research could lead to new treatments and preventive measures for osteoporosis, a condition that affects millions worldwide.
Researchers at City of Hope have identified new molecular targets on a cell receptor that play a major role in cardiovascular regulation. The findings could lead to improved drugs for heart disease, an unfortunate side effect of some cancer therapies.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
QUT researchers have created a booster vaccine using implant technology to protect wild koalas from Chlamydia disease. The new device allows for in-the-field vaccination without recapturing the animals, reducing human interference and increasing vaccination efficiency.
Researchers at Penn State have discovered a safe and efficient way to create cyclopropanes, key features in many drugs, using a previously undescribed chemical process. The new method uses visible light and common ingredients to transform alkenes into cyclopropanes with no carbene intermediate.
Researchers create accurate tumor models using 3D bioprinting and a bioink made from Laponite, improving bonding and cross-linking capabilities. The study shows that Laponite enhances biological signaling in the tumor microenvironment, increasing cell viability and promoting anti-tumor drug development.
The GEMINI blood test uses machine learning to identify cancer-causing mutations in single molecules of cell-free DNA. The test detected over 90% of lung cancers, including stage I and II cases, in a proof-of-concept study published in Nature Genetics.
Researchers have developed novel molecules that target the membrane of viruses, rather than their proteins, offering a promising new approach for treating infectious diseases. The molecules, inspired by natural peptides, disrupt the protective layers of enveloped viruses like Zika and chikungunya, while sparing human cells.
Researchers propose disease-oriented dosing of rapamycin to delay age-related diseases and increase lifespan. By decelerating early development of these diseases, rapamycin may help individuals live longer.
The study reveals altered magnitudes and coherence between oscillations in brain vasculature and brain waves in older adults. This finding has significant implications for the assessment of Alzheimer's disease and monitoring of neurodegenerative disorders.
Researchers have discovered a new way to combat fatal fungal infections by blocking the production of fatty acids, a major component of fats. The breakthrough could lead to more effective treatments against species-resistant fungi.
Researchers at Harvard developed a fiber-infused ink that allows 3D-printed heart muscle cells to align and contract like human heart cells, enabling the creation of functional heart ventricles. The innovation can be used to build life-like heart tissues with thicker muscle walls, paving the way for regenerative therapeutics.
A new study from the University of Missouri found that poverty, low health literacy, cultural beliefs, lack of infrastructure, and political issues hinder diabetes self-management for Haitian migrants. The researchers suggest targeted interventions, such as community gardens and healthcare education through local priests.
The PULSE project combines magnetic and acoustic levitation to bioprint highly sophisticated organoids that closely mimic human organs. These in vitro heart models will provide invaluable insights into cardiac physiology and pathology, enabling the development of preventive and therapeutic solutions.
Primary care physicians face challenges in prescribing medications for alcohol use disorder (MAUD), citing negative personal beliefs about treatment effectiveness and patient adherence. Despite this, they selectively prescribe MAUD to motivated patients with severe AUD or receiving concurrent treatments, highlighting the need for incre...
Researchers at UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine found that eliminating a key driver of cancer also hastened aging in mice. Despite accelerated aging, these mice lived up to 20% longer than normal mice due to lower cancer rates.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
Researchers at Tokyo University of Science successfully synthesized tanzawaic acid B in large amounts, paving the way for new antibiotic development. The breakthrough method could lead to creation of various compounds for pharmaceuticals, including new antibiotic candidates.
Researchers from Osaka University identified ten blood proteins associated with mortality in severe burns, including HBA1, TTR, and SERPINF2. These proteins may serve as targets for developing new treatment methods for burns, offering a promising direction for future research.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
The latest Alzheimer's drug, donanemab, has shown encouraging results in slowing cognitive decline by 35% compared to placebo in patients with low-to-intermediate levels of tau. However, its effectiveness is limited for those with more advanced disease, and risks include serious side effects such as amyloid-related imaging abnormalities.
A new biomarker, MTBR-tau243, tracks Alzheimer's disease progression by measuring levels of a specific form of tau in cerebrospinal fluid. The finding has major implications for diagnosing and staging the disease, and could accelerate the development of effective treatments.